I agree that its time to let the data roll in - but that still doesn't mean the drugs are the same - if he compared TH-302's active compound (the prodrug) to say ifosfamide then I'd say he was 100% right on. The discussion wasnt whether or not TH-302 works (I think it will get some impressive data from the phase 2 combo trials and we'll even see efficacy as a mono therapy) it was a discussion on his orginal comment that Telcyta = TH-302
Market Data 
Markets 
AI
